Resonant Clinical Solutions introduces a suite of asset management programs that provide information and support for sample storage strategies in clinical trials. Oct 29, 2026, 21:42 ET The leading solutions provider is launching remote, proactive, and strategic asset management programs designed to meet the evolving and complex biorepository requirements of life science companies. TORONTO, October 30, 2026 /PRNewswire/ - Resonant Clinical Solutions ("Resonant"), a global clinical solutions partner serving life science companies across the entire clinical supply chain and sample lifecycle, today announced the launch of a suite of programs designed to cover the full spectrum of biorepository asset management requirements at life science companies. The three new programs are "remote asset management" (RAM), "proactive asset management" (PAM), and "strategic asset management" (SAM). Announced at the ISBER 2026 International Biospecimen Summit in Toronto, the suite covers the various scenarios of storage strategies that companies frequently face when managing research samples. The launch comes at a time when life science companies are managing more samples at more sites, with more contract research organizations (CROs) and providers than ever before. Clinical programs are becoming increasingly complex, and pipelines are shifting toward advanced procedures such as cell and gene therapies, while expectations for data integrity, traceability, and audit readiness continue to rise. At the same time, pressure on lab space and storage budgets is increasing the importance and impact of decisions about samples - where they are stored, what is retained, whether to consolidate or change course - as a critical element of clinical operations. "Research samples represent years of investment and, in many cases, irreplaceable scientific insights, yet decisions about them are all too often made out of necessity rather than deliberately," said Christophe Berthoux, chief executive officer of Resonant Clinical Solutions. "This comprehensive suite of programs was tailored specifically to our customers' needs. Whether a team needs on-site management expertise to free up valuable R&D resources, is looking for a way to consolidate samples after a study is completed, or needs an informed assessment of the costs of changing its storage strategy, our team has the experience to support decision-making and build confidence." Three programs tailored to customer needs: Each program begins with an assessment of the customer's inventory and needs and covers different scenarios: * Remote asset management (RAM) - for organizations whose samples are located in their own labs or freezers and take up space and time that are actually needed for research and development. Resonant deploys biorepository specialists and resources to the customer's site to assess the sample inventory, storage practices, and operational requirements, manage inventories in compliance with regulations, and help move samples to Resonant's secure biorepository at the right time. Services include digital cataloging and real-time inventory tracking for full transparency and optimized sample use, provision and shipment of samples within 24 hours of request, compliant packaging and transport logistics, and support with GLP/GCP protocols and cell and gene therapy materials - thereby freeing up lab space and scientists' working time for research and development and reducing the cost of maintaining storage infrastructure. * Proactive asset management (PAM) - for organizations whose studies are complete and whose samples are still stored in a scattered manner. Resonant helps customers identify completed studies and consolidate stored samples. Resonant handles communication with partner labs and contract research organizations (CROs), creates inventories, coordinates transport logistics to its secure long-term biorepository, and provides a complete, validated inventory for audits, planning, and future studies. * Strategic asset management (SAM) - for organizations considering a change in their storage concept. For customers considering an insourcing solution or moving samples to another third-party provider, Resonant analyzes inventory and storage costs, breaks down the actual costs of the alternatives - including equipment, personnel, compliance, IT, and risk exposure - and compares them with the financial and operational impact of moving samples; Resonant then helps develop an optimized storage strategy. "We developed this suite of programs to offer tailored solutions for different customer needs," said Corey Stone, vice president and general manager - biorepository at Resonant Clinical Solutions. "We determine which program best fits a customer's current situation and then bring in the infrastructure, regulatory expertise, and experience to deliver the best solution that provides reliability, efficiency, and added value." The full range of sample asset management programs is available immediately. For more information, visit resonantclinical.com/sample-asset-management or contact us at [email protected]. Resonant is exhibiting at the ISBER 2026 International Biospecimen Summit at booth no. 14. About Resonant Clinical Solutions Resonant Clinical Solutions is a global clinical solutions partner supporting life science companies across the entire clinical supply chain and sample lifecycle. With its "Biorepository," "Kitting," and "Equipment & Ancillaries" business lines, Resonant helps its customers manage complexity, reduce risk, and support critical clinical programs worldwide. With more than 850 employees in the United States, the United Kingdom, and Europe, Resonant manages more than 100 million stored research materials, has supported more than 2,500 clinical trials, and has handled more than 20,000 shipments to customer sites. The company serves pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and diagnostics and reference laboratories. Resonant's mission is to provide its partners with comprehensive, global clinical supply chain and sample lifecycle solutions to eliminate complexity and enable them to focus on science and patients. For more information, visit resonantclinical.com.

Resonant Clinical Solutions introduces a suite of asset management programs. Oct 29, 2026, 12:08 ET -Resonant Clinical Solutions introduces a suite of asset management programs to guide and support sample storage strategies in clinical trials The leading solutions provider launches remote, proactive and strategic asset management programs designed to address the changing and complex requirements of biobanks at life sciences companies TORONTO, October 29, 2026 /PRNewswire/ - Resonant Clinical Solutions ("Resonant"), a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample life cycle, today announced the launch of a suite of programs designed to cover all biorepository asset management needs of life sciences companies. The three new programs are: remote asset management (RAM), proactive asset management (PAM) and strategic asset management (SAM). Presented during the ISBER 2026 International Biospecimen Summit in Toronto, this series of programs covers the various storage strategy scenarios that organizations typically face when managing research samples. The launch comes at a time when life sciences organizations manage more samples across more sites, CROs and vendors than ever before. Clinical programs are increasingly complex and projects are moving toward advanced modalities such as cell and gene therapies, while expectations regarding data integrity, chain of custody and audit readiness continue to rise. At the same time, pressure on laboratory space and storage budgets increases the importance and impact of decisions about samples, where to store them, what to retain, whether to consolidate them or change strategy, as a critical element of clinical operations. "Research samples represent years of investment and, in many cases, irreplaceable science; yet decisions about them are too often made by inertia rather than by planning," said Christophe Berthoux, CEO of Resonant Clinical Solutions. "This comprehensive suite of programs was designed with our clients' needs in mind. Whether a team needs on-site management expertise to free up valuable R&D resources, a path to consolidate samples after study completion, or an informed perspective on the cost of changing storage strategy, our team has the expertise needed to support decision-making and instill confidence." Three programs tailored to customer needs Each program begins with an assessment of the customer's inventory and needs, addressing different scenarios: * Remote asset management: aimed at organizations whose samples are in their own laboratories or freezers, taking up space and time needed for R&D activities. Resonant deploys biorepository specialists and resources to the customer's facilities to assess the sample inventory, storage practices and operational needs; manage assets in accordance with current regulations; and facilitate transfer of samples to Resonant's secure biorepository at the appropriate time. Services include digital cataloging and real-time inventory tracking, ensuring full sample visibility and optimizing use, retrieval and shipment of samples within 24 hours of request, compliant packaging and transport logistics, as well as support for GLP/GCP protocols and materials intended for cell and gene therapies. All of this makes it possible to recover laboratory space and scientific staff time for R&D, in addition to reducing costs associated with maintaining storage infrastructure. * Proactive asset management: aimed at organizations whose studies have concluded but whose samples remain dispersed. Resonant helps its clients identify completed studies and consolidate stored samples. Resonant handles communication with collaborating laboratories and contract research organizations (CROs), collects inventories, coordinates transfer logistics to its secure biorepository for long-term storage, and delivers a complete, validated inventory ready for audits, planning processes and future studies. * Strategic asset management: for organizations evaluating a change in their storage approach. For clients considering internalizing the service or transferring their samples to another external provider, Resonant analyzes inventory and storage costs, breaks down the true cost of alternatives including equipment, personnel, regulatory compliance, IT and risk exposure, compares it with the financial and operational impact of transferring the samples, and then helps define an optimized storage strategy. "We designed this suite of programs to offer tailored solutions adapted to our clients' different needs," said Corey Stone, vice president and general manager of the biorepository division at Resonant Clinical Solutions. "We identify which program best fits each client's current situation and then provide the infrastructure, regulatory rigor and expertise needed to deliver an optimal solution that ensures reliability, efficiency and value." The full range of sample asset management programs is now available. For more information, visit resonantclinical.com/sample-asset-management or contact us at [email protected]. At the ISBER 2026 International Biospecimen Summit, Resonant will be at booth no. 14. About Resonant Clinical Solutions Resonant Clinical Solutions is a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample life cycle. Through its biorepository, kit and equipment preparation, and ancillary materials divisions, Resonant helps its clients manage complexity, reduce risk and support critical clinical programs worldwide. With more than 850 employees in the United States, United Kingdom and Europe, Resonant manages the storage of more than 100 million research assets; it has also supported more than 2,500 clinical trials and facilitated more than 20,000 shipments to its clients' facilities. The company serves pharmaceutical and biotechnology companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), as well as diagnostic and reference laboratories. Resonant's mission is to equip its partners with comprehensive, global solutions for the clinical supply chain and sample life cycle, eliminating complexity and enabling them to focus on science and patients. For more information, visit resonantclinical.com.